Press

Stockholm, November 8, 2021 - Intervacc AB (“Intervacc”) announces that the United States Patent and Trademark Office has granted an approval for Intervacc's patent application in the United States for a vaccine against ... Read more

Stockholm, September 17, 2021 - Intervacc AB (“Intervacc”) announced today that the Veterinary Medicines Directorate (VMD) of the United Kingdom has granted a Marketing Authorisation for Strangvac^® within the ... Read more

Stockholm August 25, 2021 - Intervacc has stated in the published financial calendar that the report for the first half of 2021 would be made public on September 3, 2021. The report will be made public on August 31, ... Read more

Stockholm, August 23, 2021 - Intervacc AB (“Intervacc”) announced today that the Norwegian Medicines Agency (NoMA) has granted a marketing authorisation for Strangvac^® within Norway. Strangvac^® is ... Read more